Biferrocene-Based Diphosphine Ligands: Synthesis and Application of Walphos Analogues in Asymmetric Hydrogenations.

A total of four biferrocene-based Walphos-type ligands have been synthesized, structurally characterized, and tested in the rhodium-, ruthenium- and iridium-catalyzed hydrogenation of alkenes and ketones. Negishi coupling conditions allowed the biferrocene backbone of these diphosphine ligands to be built up diastereoselectively from the two nonidentical and nonracemic ferrocene fragments (R)-1-(N,N-dimethylamino)ethylferrocene and (SFc)-2-bromoiodoferrocene. The molecular structures of (SFc)-2-bromoiodoferrocene, the coupling product, two ligands, and the two complexes ([PdCl2(L)] and [RuCl(p-cymene)(L)]PF6) were determined by X-ray diffraction. The structural features of complexes and the catalysis results obtained with the newly synthesized biferrocene-based ligands were compared with those of the corresponding Walphos ligands.

Highly efficient asymmetric synthesis of sitagliptin.

A highly efficient synthesis of sitagliptin, a potent and selective DPP-4 inhibitor for the treatment of type 2 diabetes mellitus (T2DM), has been developed. The key dehydrositagliptin intermediate 9 is prepared in three steps in one pot and directly isolated in 82% yield and >99.6 wt % purity. Highly enantioselective hydrogenation of dehydrositagliptin 9, with as low as 0.15 mol % of Rh(I)/(t)Bu JOSIPHOS, affords sitagliptin, which is finally isolated as its phosphate salt with nearly perfect optical and chemical purity. This environmentally friendly, 'green' synthesis significantly reduces the total waste generated per kilogram of sitagliptin produced in comparison with the first-generation route and completely eliminates aqueous waste streams. The efficiency of this cost-effective process, which has been implemented on manufacturing scale, results in up to 65% overall isolated yield.

Synthesis, coordination behaviour, structural features and use in asymmetric hydrogenations of bifep-type biferrocenes.

A protocol for the synthesis of C2- and C1-symmetric 2,2''-diarylphosphino-substituted biferrocenes (bifep-type ligands) is presented and the preparation of four representatives is described [(Sp,Sp)-2-R1(2)P-2''- R2(2)P-1,1''-biferrocene; (bifep): R1=R2=Ph; : R1=Ph, R2=Cy; : R1=R2=3,5-Me2C6H3; : R1=3,5-Me(2-)4-OMe-C6H2, R2=3,5-(CF3)2C6H3]. In addition, the synthesis of three palladium(II) complexes ([PdX2(L)], : L=, X=Cl; : L=, X=Cl; : L=, X=C6F5 and of four bifep ruthenium complexes (: [RuCl(p-cymene)()]PF6; : [RuI(p-cymene)()]PF6; : [RuCl(benzene)()]PF(6); : [RuI(p-cymene)()]I) is reported. In the solid state the biferrocene unit of complexes , and adopt either a (P)-shaped () or an (M)-shaped (, ) conformation. In solution, palladium complexes and are present as equilibrium mixtures of rapidly interconverting (P)- and (M)-shaped conformers. Rhodium- and iridium-mediated asymmetric hydrogenations of a number of olefins and one imine give products with only low to moderate enantiomeric excess, while in the ruthenium-catalyzed hydrogenation of ketones a maximum e.e. of 82% is obtained. The low enantioselectivities are assumed to be related to the conformational flexibility of bifep-type ligands.

SAR, pharmacokinetics, safety, and efficacy of glucokinase activating 2-(4-sulfonylphenyl)-N-thiazol-2-ylacetamides: discovery of PSN-GK1.

Allosteric activators of the glucose-sensing enzyme glucokinase (GK) are currently attracting much interest as potential antidiabetic therapies because they can achieve powerful blood glucose lowering through actions in multiple organs. Here, the optimization of a weakly active high-throughput screening hit to (2 R)-2-(4-cyclopropanesulfonylphenyl)- N-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide (PSN-GK1), a potent GK activator with an improved pharmacokinetic and safety profile, is described. Following oral administration, this compound elicited robust glucose lowering in rats.

Solphos: a new family of efficient biaryl diphosphine ligands.

Solphos (7,7'-bis(diarylphosphino)-3,3',4,4'-tetrahydro-4,4'-dimethyl-8,8'-bis-2H-1,4-benzoxazine) is a new modular atropisomeric biaryl ligand with a very attractive activity profile. A technically feasible synthesis is described allowing the synthesis of various derivatives of enantiopure ligand on a technical scale. Very good catalytic performances have been demonstrated for the following transformations: Ru-catalyzed hydrogenation of various beta-keto esters (95-99 % ee, s/c up to 100,000), of acetyl acetone (>99 % ee, dl/meso>98:2), and of an exocyclic alpha,beta-unsaturated acid (98.6 % ee, s/c 250). In several cases, the nature of the PAr(2) moiety had a significant effect on the enantioselectivity. Furthermore, Rh and Ir Solphos complexes achieved high enantioselectivities for a novel synthesis of 3,3-disubstituted phthalides and the reductive coupling of alkynes with N-sulfonyl imines, respectively.

From a chiral switch to a ligand portfolio for asymmetric catalysis.

This Account is divided into two sections. In the first section, the development of an enantioselective manufacturing process for ( S)-metolachlor, the active ingredient of the grass herbicide Dual Magnum, is described. This is today's largest application of asymmetric catalysis, and the Ir-Xyliphos hydrogenation catalyst achieves unprecedented 2 millions turnovers. The development started in 1982 and ended when the first production batch was run in November 1996. The strategies and approaches used for attaining the elusive goal are described, and the lessons learned are discussed. In the second section, the development and performance of a portfolio of chiral diphosphines for industrial asymmetric applications are described. Central to the portfolio is the idea of modular ligand families, i.e., diphosphines with the same backbone, where steric and electronic properties are easily tuned by the choice of the substituents at the phosphorous atoms.

Asymmetric homogeneous hydrogenation of 2,5-disubstituted furans.

A homogeneous catalyst system for the asymmetric cis-hydrogenation of 2,5-disubstituted furans leading to 2',3'-dideoxynucleoside analogues is described. Best enantioselectivities (ee values of up to 72%) were obtained with cationic rhodium complexes ligated by diphospholanes of the butiphane family. The selectivity of the hydrogenation was reversed by the addition of a base or a polar protic solvent in certain cases. Ferrocene- and proline-based systems gave significant, but lower, ee values.

Highly efficient synthesis of beta-amino acid derivatives via asymmetric hydrogenation of unprotected enamines.

A direct asymmetric hydrogenation of unprotected enamino esters and amides is described. Catalyzed by Rh complexes with Josiphos-type chiral ligands, this method gives beta-amino esters and amides in high yield and high ee (93-97% ee). No acyl protection/deprotection is required.

Chiral iridium [corrected] xyliphos complexes for the catalytic imine hydrogenation leading to the metolachlor herbicide: isolation of catalyst-substrate adducts.

Iridium complexes relevant to the catalytic enantioselective hydrogenation of 2-methyl-6-ethylphenyl-1'-methyl-2'-methoxyethylimine (MEA-imine, 1) in the Syngenta Metolachlor (3) process were prepared and characterized. Reaction of the diphosphane (S)-1-[(R)-2-(diphenylphosphanyl)ferrocenyl]ethyldi(3,5-xylyl)phosphane ((S)-(R)-Xyliphos, (S)-(R)-4) with [Ir(2)(micro-Cl)(2)(cod)(2)] (cod=1,5-cyclooctadiene) afforded [Ir(Cl)(cod)[(S)-(R)-4]] (7), which reacted with AgBF(4) to form [Ir(cod)[(S)-(R)-4]]BF(4) (8). Complexes 7 and 8 reacted with iodide to yield [Ir(I)(cod)[(S)-(R)-4]] (9). When 9 was treated with one and two equivalents of HBF(4), two isomers of the cationic Ir(III) iodo hydrido complex [Ir(I)(H)(cod)[(S)-(R)-4]]BF(4) were solated (10 and 11, respectively). Complex 9 was oxidized with one equivalent of I(2) to give the iodo-bridged dinuclear species [Ir(2)I(2)(micro-I)(3)[(S)-(R)-4](2))]I (12). [Ir(2)(micro-Cl)(2)(coe)(4)] (coe=cyclooctene) reacted with (S)-(R)-4 to yield the chloro-bridged dinuclear complex [Ir(2)(micro-Cl)(2)[(S)-(R)-4](2)] (13). Complexes 7-12 were structurally characterized by single-crystal X-ray diffraction and tested as single-component catalyst precursors for enantioselective hydrogenation of MEA-imine. Complex 10 and dinuclear complex 12 gave the best catalytic results. Efforts were also directed at isolating substrate- or product-catalyst adducts: Treatment of 8 with 2,6-dimethylphenyl-1'-methyl-2'-methoxyethylimine (DMA-imine, 14, a model for 1) under H(2) allowed four isomers of [Ir(H)(2)[(S)-(R)-4](14)]BF(4) (18-21) to be isolated. These analytically pure isomers were fully characterized by 2D NMR techniques. X-ray structural analysis of an Ir(I)-imine adduct, namely, [Ir(C(2)H(4))(2)(14)]BF(4) (25), which was prepared by reacting [IrCl(C(2)H(4))(4)] with [Ag(14)(2)]BF(4) (16), confirmed the kappa(2) coordination mode of imine 14.

Exploring stereogenic phosphorus: synthetic strategies for diphosphines containing bulky, highly symmetric substituents.

Diphosphine ligands bearing highly symmetric, bulky substituents at a stereogenic P atom were prepared, exploiting established protocols, which include the use of chiral synthons such as 3,4-dimethyl-2,5-diphenyl-1,3,2-oxazaphospholidine-2-borane (3a) and phenylmethylchlorophosphine borane (10) and the enantioselective deprotonation of dimethylarylphosphine boranes. However, only (Bu(t)())(Me)PCH(2)CH(2)P(Bu(t)Me (8a) could be prepared from 3a. The diphosphines (S,S)-1,2-bis(mesitylmethylphosphino)ethane, ((S,S)-8b) and (S,S)-1,2-bis(9-anthrylmethylphosphino)ethane ((S,S)-8c), which contain 2,6-disubstituted aryl P-substituents, were prepared by Evans' sparteine-assisted enantioselective deprotonation of P(Ar)(Me)(2)(BH(3)) (Ar = mesityl or 9-anthryl), but the enantioselectivity did not exceed 37% ee. The asymmetrically substituted, methylene-bridged diphosphine (2R,4R)-(Ph)(CH(3))PCH(2)P(Mes)(CH(3)) ((2R,4R)-12) (Mes = mesityl) was prepared by the newly developed stereospecific reaction of the enantiomerically pure chlorophosphine borane PCl(Ph)(Me)(BH(3)) (10) with the racemic, monolithiated dimethylmesitylphosphine borane P(Mes)(Me)(CH(2)Li)(BH(3)). Diastereomerically pure (2R,4R)-12 was obtained with 86% ee. The rhodium(I) derivatives [Rh(COD)(P-P)]BF(4) containing the diphosphine ligands 8a, 8b, and 12, as well as the previously reported (S,S)-1,2-bis(1-naphthylphenylphosphino)ethane ((S,S)-8d), were prepared and tested in the enantioselective catalytic hydrogenation of acetamidocinnamates. The best catalytic result (98.6% ee) was obtained with [Rh(COD)(8d)](+) as catalyst and methyl Z-alpha-acetamidocinnamate as substrate. Some of the catalytic results are discussed in terms of the preferred conformations of the substituents at phosphorus, as calculated by molecular modeling.